Hangzhou Tigermed Consulting Co., Ltd
300347
株式のランク
#3216
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
株価
$7.44
時価総額
$5.49B
変化（1日）
-2.99%
変化（1年）
-0.42%
国
CN
取引 Hangzhou Tigermed Consulting Co., Ltd (300347)
カテゴリー
Healthcare
Hangzhou Tigermed Consulting Co., Ltd（300347）の収益
Jun 2026 時点の収益 TTM: $1.09B
Hangzhou Tigermed Consulting Co., Ltd の最新の財務報告によると、現在の収益 (TTM) は $1.09B です。2024 年には $904.65M の収益があり、これは 2023 年の $1.04B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Hangzhou Tigermed Consulting Co., Ltd の収益履歴（2009 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.09B | 11.78% |
| 2025 | $976.62M | 7.96% |
| 2024 | $904.65M | -13.28% |
| 2023 | $1.04B | 27.17% |
| 2022 | $820.27M | 67.86% |
| 2020 | $488.66M | 21.38% |
| 2019 | $402.58M | 20.37% |
| 2018 | $334.47M | 28.99% |
| 2017 | $259.30M | 53.27% |
| 2016 | $169.17M | 14.79% |
| 2015 | $147.37M | 46.15% |
| 2014 | $100.83M | 81.75% |
| 2013 | $55.48M | 36.03% |
| 2012 | $40.78M | 33.03% |
| 2011 | $30.66M | 64.72% |
| 2010 | $18.61M | 102.35% |
| 2009 | $9.20M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,056.47% |
US
|
|
| $2.23B | 104.10% |
US
|
|
| $15.74B | 1,342.29% |
AU
|
|
| $9.57B | 776.91% |
BE
|
|
| $6.02B | 451.59% |
NL
|
